SCHEMBL23927466

SCHEMBL23927466

CCOC(=O)c1nnc(CN2CCCC2)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.43
▸ KDM4E B2RXH2 5/20 0.43
▸ TSHR P16473 3/20 0.43
▸ LMNA P02545 2/20 0.42
▸ GAA P10253 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ POLB P06746 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23927478 0.87 ALDH1A1 (0.48) ALDH1A1KDM4ETSHRLMNAGAA
SCHEMBL9920410 0.77 KDM4E (0.49) ALDH1A1KDM4ELMNAGAAHPGD
SCHEMBL22272842 0.76 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAGAAHPGD
SCHEMBL22272845 0.74 KDM4E (0.46) ALDH1A1KDM4ELMNAGAAHPGD
SCHEMBL22272515 0.73 KDM4E (0.40) ALDH1A1KDM4ETSHRLMNAGAA
SCHEMBL15964597 0.73 LMNA (0.42) ALDH1A1KDM4ETSHRLMNAGAA
SCHEMBL1935643 0.73 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAGAAHPGD
SCHEMBL22272514 0.73 KDM4E (0.42) ALDH1A1KDM4ETSHRLMNAGAA
SCHEMBL23927505 0.72 LMNA (0.44) ALDH1A1KDM4ETSHRLMNAGAA
SCHEMBL17324360 0.72 LMNA (0.44) ALDH1A1KDM4ETSHRLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 — — US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 — — EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 — — US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 — — CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 — — EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 ALDH1A1 4164/4885KDM4E 1934/4885TSHR 2607/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 ALDH1A1 4164/4885KDM4E 1934/4885TSHR 2607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback